Pfiz­er cel­e­brates ac­cel­er­at­ed win for po­ten­tial mul­ti­ple myelo­ma block­buster

Pfiz­er has se­cured an ac­cel­er­at­ed ap­proval for El­rex­fio, a po­ten­tial mul­ti­ple myelo­ma block­buster that Pfiz­er ex­pects could be­come a “multi­bil­lion-dol­lar fran­chise.”

El­rex­fio, al­so known as el­ranatam­ab, will be avail­able for re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma pa­tients who’ve had at least four pri­or ther­a­pies, in­clud­ing a pro­tea­some in­hibitor, an im­munomod­u­la­to­ry agent and an an­ti-CD38 mon­o­clon­al an­ti­body, Pfiz­er an­nounced Mon­day. The drug tar­gets BC­MA on myelo­ma cells and CD3 on T cells, prompt­ing the T cells to at­tack the myelo­ma cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER